Literature DB >> 4543024

Human lymphocytes bear membrane receptors for C3b and C3d.

A Eden, G W Miller, V Nussenzweig.   

Abstract

Human peripheral blood lymphocytes have membrane receptors for EAC43b (sheep erythrocytes sensitized with antibody and complement) and also for EAC43d, obtained by treating EAC43b with C3b inactivator. Human granulocytes bind only EAC43b, C3 fragments obtained by limited trypsin digestion of purified human C3 display both C3b and C3d sites, since they inhibit rosette formation of lymphocytes with EAC43b and EAC43d. These findings raise the possibility that C3b and C3d receptor sites may be selectively distributed among normal subpopulations of B lymphocytes as well as among leukemic leukocytes.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4543024      PMCID: PMC302601          DOI: 10.1172/JCI107525

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  Immune hemolysis: a simplified method for the preparation of EAC'4 with guinea pig or with human complement.

Authors:  T Borsos; H J Rapp
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

2.  Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia.

Authors:  S Pincus; C Bianco; V Nussenzweig
Journal:  Blood       Date:  1972-09       Impact factor: 22.113

3.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

4.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

5.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

6.  Three naturally-occurring inhibitors of components of complement in guinea pig and rabbit serum.

Authors:  N Tamura; R A Nelson
Journal:  J Immunol       Date:  1967-09       Impact factor: 5.422

7.  Immunological induction of increased vascular permeability. II. Two mechanisms of histamine release from rabbit platelets involving complement.

Authors:  P M Henson; C G Cochrane
Journal:  J Exp Med       Date:  1969-01-01       Impact factor: 14.307

8.  Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes.

Authors:  G D Ross; E M Rabellino; M J Polley; H M Grey
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

9.  Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG).

Authors:  B Mantovani; M Rabinovitch; V Nussenzweig
Journal:  J Exp Med       Date:  1972-04-01       Impact factor: 14.307

10.  Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5.

Authors:  H S Shin; M R Smith; W B Wood
Journal:  J Exp Med       Date:  1969-12-01       Impact factor: 14.307

View more
  36 in total

1.  Activated guinea-pig C3 and the immune adherence receptor (a complement receptor) on cell membranes.

Authors:  H Okada; N Okada
Journal:  Immunology       Date:  1975-06       Impact factor: 7.397

2.  The lymphocyte plasma membrane: locus of control in the immune response.

Authors:  L M Jerry; A K Sullivan
Journal:  In Vitro       Date:  1976-03

3.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Human lymphocyte complement receptors. Quantitative requirements for C3 of normal and chronic lymphocyte leukemia lymphocytes.

Authors:  G L Logue; H J Cohen
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

5.  Bone marrow-derived lymphoid cell lines from patients with agammaglobulinemia.

Authors:  J Schwaber; H Lazarus; F S Rosen
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

6.  BSA-anti-BSA immune complexes formed in the presence of human complement do not bind to autologous red blood cells.

Authors:  L Varga; E Thiry; G Füst
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

7.  The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation.

Authors:  T F Tedder; J J Weis; L T Clement; D T Fearon; M D Cooper
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

8.  Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors.

Authors:  K B Pryzwansky; J D Lambris; E K MacRae; J H Schwab
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

9.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes.

Authors:  J J Weis; T F Tedder; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

10.  Binding of immunoglobulin- and complement-coated erythrocytes to human neutrophil subpopulations.

Authors:  S C Whited; M Santaella; M M Frank; T Gaither; J I Gallin
Journal:  Inflammation       Date:  1981-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.